← Evidence map

ArticleGynecologic oncology reports2026

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials.

Alex A Francoeur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. | OpenQuestion